Literature DB >> 2305929

Serous borderline tumors of the peritoneum.

D A Bell1, R E Scully.   

Abstract

The clinicopathological features of 25 cases of peritoneal serous neoplasms histologically identical to noninvasive implants of ovarian serous borderline tumors but with minimal or no ovarian surface involvement were reviewed. The patients ranged in age from 19 to 53 (mean, 31) years; 18 of them were under 35 years of age. Infertility and abdominal pain were the most common presenting complaints. An extraovarian mass was present in two patients; adhesions or granularity of peritoneal surfaces were described in 23 of them. In 21 cases only the pelvic peritoneum was involved; the upper abdominal peritoneum was involved additionally in four cases. Most of the women were treated by hysterectomy, bilateral salpingo-oophorectomy, and omentectomy; six of them received chemotherapy postoperatively and two received both chemotherapy and radiation therapy. Nine women had a more limited operation to preserve their fertility. The 25 patients were followed for 4 to 13.9 (mean, 8) years. There was no clinical evidence of recurrence in 21 women. Borderline tumor recurred in two patients, who remained well for 1.7 and 2 years after excision of the recurrent tumor. Invasive low-grade serous carcinoma of the peritoneum developed in one woman who was living with extensive intra-abdominal tumor at the last follow-up examination. One woman died of disseminated SBT, which was diagnosed cytologically but not confirmed by biopsy.

Entities:  

Mesh:

Year:  1990        PMID: 2305929     DOI: 10.1097/00000478-199003000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

1.  Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary.

Authors:  Catherine Uzan; Aminata Kane; Annie Rey; Sebastien Gouy; Sophie Camatte; Patricia Pautier; Catherine Lhommé; Christine Haie-Meder; Pierre Duvillard; Philippe Morice
Journal:  Oncologist       Date:  2011-01-27

2.  Non-ovarian peritoneal papillary serous carcinoma with high CA125 levels.

Authors:  H R Rosen; A C Rosen; J Preiser; M Stierer; M Klein; H Hanak
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

3.  CT appearance of primary peritoneal serous borderline tumour: a rare epithelial tumour of the peritoneum.

Authors:  H S Go; H S Hong; J W Kim; J Y Woo
Journal:  Br J Radiol       Date:  2012-01       Impact factor: 3.039

4.  Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis.

Authors:  Robert J Kurman; Russell Vang; Jette Junge; Charlotte Gerd Hannibal; Susanne K Kjaer; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

Review 5.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

6.  Malignant mesothelioma in women.

Authors:  A Dawson; A R Gibbs; F D Pooley; D M Griffiths; J Hoy
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

7.  The differential diagnosis of primary peritoneal papillary tumors.

Authors:  G Gitsch; U Tabery; W Feigl; G Breitenecker
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

8.  [Pathologic and anatomic evidence of peritoneal metastases].

Authors:  I Tischoff; A Tannapfel
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

9.  DNA-cytophotometry and immunocytochemistry in ovarian tumours of borderline malignancy and related peritoneal lesions.

Authors:  B C Padberg; H E Stegner; S von Sengbusch; H Arps; S Schröder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 10.  [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].

Authors:  Volker Neumann; Stefan Löseke; Andrea Tannapfel
Journal:  Med Klin (Munich)       Date:  2009-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.